Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$19.77
-1.5%
$18.24
$8.02
$21.76
$9.82B1.655.96 million shs4.60 million shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
Moderna, Inc. stock logo
MRNA
Moderna
$26.83
-2.5%
$25.94
$23.15
$59.73
$10.48B2.0110.88 million shs10.05 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$16.04
-0.5%
$13.35
$8.73
$16.79
$10.95B1.26.22 million shs4.85 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-1.38%-1.96%+6.74%+34.67%+37.44%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
Moderna, Inc. stock logo
MRNA
Moderna
-1.40%-2.96%+12.51%-18.16%-53.23%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+0.56%+0.88%+19.58%+41.90%+40.05%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$19.77
-1.5%
$18.24
$8.02
$21.76
$9.82B1.655.96 million shs4.60 million shs
MorphoSys AG stock logo
MOR
MorphoSys
$18.96
$18.96
$4.18
$19.50
$2.86B1.21.02 million shsN/A
Moderna, Inc. stock logo
MRNA
Moderna
$26.83
-2.5%
$25.94
$23.15
$59.73
$10.48B2.0110.88 million shs10.05 million shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$16.04
-0.5%
$13.35
$8.73
$16.79
$10.95B1.26.22 million shs4.85 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-1.38%-1.96%+6.74%+34.67%+37.44%
MorphoSys AG stock logo
MOR
MorphoSys
0.00%0.00%0.00%0.00%0.00%
Moderna, Inc. stock logo
MRNA
Moderna
-1.40%-2.96%+12.51%-18.16%-53.23%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
+0.56%+0.88%+19.58%+41.90%+40.05%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.91
Moderate Buy$19.14-3.17% Downside
MorphoSys AG stock logo
MOR
MorphoSys
0.00
N/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
2.00
Hold$41.8155.84% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.80
Moderate Buy$19.9424.30% Upside

Current Analyst Ratings Breakdown

Latest MOR, ROIV, ELAN, and MRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/10/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetEqual Weight$31.00 ➝ $32.00
10/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/8/2025
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
10/7/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralOverweight$18.00 ➝ $24.00
10/3/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
9/27/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
9/27/2025
Moderna, Inc. stock logo
MRNA
Moderna
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D+)
9/24/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$18.00 ➝ $23.00
9/18/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$18.00 ➝ $20.00
(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.48B2.19$2.19 per share9.03$12.33 per share1.60
MorphoSys AG stock logo
MOR
MorphoSys
$238.28M11.99N/AN/A$0.35 per share54.17
Moderna, Inc. stock logo
MRNA
Moderna
$3.06B3.43N/AN/A$28.33 per share0.95
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M377.05N/AN/A$7.45 per share2.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.8622.9922.213.759.68%7.04%3.45%11/5/2025 (Estimated)
MorphoSys AG stock logo
MOR
MorphoSys
-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$7.53N/AN/AN/A-94.31%-25.96%-20.09%11/6/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$171.98M-$0.70N/AN/AN/A-2,111.79%-15.90%-14.95%11/11/2025 (Estimated)

Latest MOR, ROIV, ELAN, and MRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$1.95N/AN/AN/A$893.29 millionN/A
11/5/2025Q3 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.13N/AN/AN/A$1.09 billionN/A
8/7/2025Q2 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.1989$0.26+$0.0611$0.02$1.19 billion$1.24 billion
8/1/2025Q2 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.99-$2.13+$0.86-$2.13$116.26 million$142.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
MorphoSys AG stock logo
MOR
MorphoSys
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.61
2.60
1.40
MorphoSys AG stock logo
MOR
MorphoSys
4.98
1.38
1.38
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.93
3.77
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
40.54
40.54

Institutional Ownership

CompanyInstitutional Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
MorphoSys AG stock logo
MOR
MorphoSys
18.38%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%

Insider Ownership

CompanyInsider Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
MorphoSys AG stock logo
MOR
MorphoSys
0.05%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.81 million492.39 millionOptionable
MorphoSys AG stock logo
MOR
MorphoSys
730150.62 million150.55 millionNot Optionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800390.58 million347.62 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860682.88 million609.13 millionOptionable

Recent News About These Companies

Goldman Sachs Sticks to Their Buy Rating for Roivant Sciences (ROIV)
Roivant Sciences Rises on Nasdaq Composite with Strong Momentum

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$19.77 -0.30 (-1.49%)
Closing price 03:59 PM Eastern
Extended Trading
$19.76 0.00 (-0.03%)
As of 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

MorphoSys stock logo

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)
As of 10/9/2025

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Moderna stock logo

Moderna NASDAQ:MRNA

$26.83 -0.70 (-2.54%)
Closing price 04:00 PM Eastern
Extended Trading
$26.34 -0.49 (-1.83%)
As of 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$16.04 -0.08 (-0.50%)
Closing price 04:00 PM Eastern
Extended Trading
$16.04 0.00 (-0.01%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.